Every 8-K that Pliant Therapeutics, Inc. (PLRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLRX filings page.
Pliant Therapeutics, Inc. reported second quarter 2026 results and provided a corporate update centered on its oncology and drug-delivery platforms. Lead asset PLN-101095, an oral dual-selective inhibitor of αvβ8 and αvβ1 integrins, is being evaluated in FORTIFY, a Phase 1a/1b trial in immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.
The company highlighted that FORTIFY enrollment across three indication-expansion cohorts remains strong and ahead of schedule, with up to 102 patients planned and interim data expected in 2027. Updated Phase 1 monotherapy biomarker data showed coordinated T‑cell reactivation signals in responders, including increases in IFN‑γ, CXCL9 and granzyme‑B, suggesting a shift in the tumor microenvironment that may potentially resensitize tumors to pembrolizumab.
Pliant is advancing an integrin-targeted delivery platform for tissue-specific delivery of drug payloads, including siRNAs, and plans additional details, including initial treatment indications, in the second half of 2026. For the quarter, research and development expenses were $16.7 million and general and administrative expenses were $7.1 million, contributing to a net loss of $22.4 million, all substantially lower than the prior-year period. Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026, which the company expects to fund operations into the second half of 2028.
Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members effective July 9, 2026, and appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director to fill the new seats. Both have been determined to be independent directors under SEC and Nasdaq rules. Dr. Iannone joins the Research and Development Committee, while Dr. Borellini becomes its chairperson. Each new director will receive an annual cash retainer of $40,000, pro-rated for partial service periods; Dr. Iannone will receive an additional $7,500 for R&D Committee membership and Dr. Borellini $15,000 for serving as R&D Committee chair. On the effective date, each was granted an option to purchase 60,000 shares of common stock, vesting in substantially equal monthly installments over three years, subject to continued Board service. The company also entered into its standard indemnification agreements with both directors.
Pliant Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 15, 2026 record date, 61,914,664 shares of common stock were outstanding and entitled to vote.
Stockholders elected Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA as Class III directors to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Pliant Therapeutics reported first quarter 2026 results and highlighted progress in its oncology and delivery platforms. The company’s lead program, PLN-101095, advanced with first patient dosed in FORTIFY, a Phase 1b indication expansion trial in checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027.
Updated Phase 1 data for PLN-101095 presented at AACR 2026 showed one confirmed complete response, two confirmed partial responses and one unconfirmed partial response in heavily pretreated patients, with biomarker changes consistent with enhanced immune activity and a generally well tolerated safety profile. Pliant is also advancing an integrin-targeted delivery platform for tissue-specific siRNA delivery.
Financially, first quarter 2026 research and development expenses were $13.6 million and general and administrative expenses were $8.2 million, both sharply lower than the prior-year period. Net loss narrowed to $20.0 million, or $0.32 per share, and the company ended March 31, 2026 with $172.4 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2028.
Pliant Therapeutics, Inc. announced that three directors — David E.I. Pyott, Katharine Knobil, M.D., and Suzanne Bruhn, Ph.D. — will retire from the Board and all committees effective at the 2026 Annual Meeting, with each stating the decision was not due to any disagreement with the company.
The Board also approved an option repricing effective April 17, 2026, resetting all employee stock options granted on or before March 1, 2025 under its equity plans to an exercise price of $1.33 per share, the closing market price on the Effective Date. To benefit from the new price, employees must remain in service through a defined Retention Period — 18 months for the executive leadership team and 12 months for other employees — subject to specified exceptions such as certain corporate transactions, qualifying terminations, death or disability. If an employee is terminated for cause, resigns early without good reason (for vice presidents and above), or exercises options before the Retention Period ends, the options revert to their original higher exercise price. The company states the repricing is intended to retain and motivate employees, including executive officers, without additional equity dilution or cash compensation.
Pliant Therapeutics, Inc. updated its at-the-market stock offering arrangements. The company has a Sales Agreement with Leerink Partners LLC that allows it to offer and sell common stock with an aggregate offering price of up to $50.0 million under an at-the-market prospectus. Effective March 27, 2026, it terminated a prior Controlled Equity Offering℠ Sales Agreement with Cantor Fitzgerald & Co., with no termination penalties and no shares having been sold under the 2021 agreement.
Pliant Therapeutics reported fourth quarter 2025 results alongside a major update on its oncology pipeline. Lead candidate PLN-101095, an oral dual-selective αvβ8/αvβ1 inhibitor, showed deep and durable responses in a Phase 1 trial in immune checkpoint inhibitor–refractory solid tumors, including one confirmed complete response and three partial responses among 10 secondary ICI refractory patients. The company has begun an accelerated development plan with a Phase 1b indication expansion trial in non-small cell lung cancer, clear cell renal cell carcinoma and tumors with high tumor mutational burden, and Phase 1 data will be presented at the AACR Annual Meeting 2026.
Research and development expenses fell to $15.6 million from $38.8 million in the prior-year quarter, and general and administrative expenses declined to $8.0 million from $14.5 million, mainly due to discontinuation of BEACON-IPF and workforce restructuring. Quarterly net loss narrowed to $23.6 million from $49.7 million, and full-year 2025 net loss was $149.3 million versus $210.3 million in 2024. As of December 31, 2025, Pliant held $192.4 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2028.
Pliant Therapeutics has extended its stockholder rights plan by one year. The company and Computershare Trust Company, N.A., amended their Stockholder Rights Agreement so that the associated rights now expire at 5:00 p.m. New York City time on March 11, 2027, instead of March 11, 2026.
The plan is intended to make it harder for any person, entity or group to gain control of the company through open market share purchases without paying all stockholders an appropriate control premium or giving the board enough time to evaluate alternatives. The company states the change was not made in response to any specific takeover offer and is not meant to block mergers or other business combinations approved by the board.
Pliant Therapeutics, Inc. reported an executive leadership change, appointing Minnie Kuo as Chief Operating Officer effective December 10, 2025. She previously served as the company’s Chief Development Officer after joining in September 2023.
Kuo is described as an experienced biotechnology and pharmaceutical executive with more than 20 years of multinational clinical development experience across respiratory, oncology, neurodegenerative, inflammatory, and infectious diseases. Her prior roles included senior positions at Vir Biotechnology, Nektar Therapeutics, Gilead Sciences, Roche/Genentech, and several clinical research organizations.
The company states that Ms. Kuo received no additional compensation at the time of her appointment as Chief Operating Officer and that there are no disclosable family relationships or related-party transactions associated with her appointment.
Pliant Therapeutics filed an 8‑K announcing it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in this report, including the exhibit, is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.
Pliant Therapeutics reported an executive change: Chief Business Officer Hans Hull resigned effective October 20, 2025. The company stated the resignation was not due to any disagreement related to operations, policies, or practices. The report was signed by Keith Cummings, M.D., MBA, in his capacity as Chief Financial Officer.
Pliant Therapeutics, Inc. (PLRX) fully repaid its debt facility, making a voluntary payoff of $32.4 million on October 14, 2025 to settle all outstanding principal, accrued interest, fees and expenses under its Amended and Restated Loan and Security Agreement with Oxford Finance. With receipt of the payoff, all obligations were discharged and the loan documents were terminated.
The agreement allowed up to $150 million in term loans; the company had borrowed $30 million. The loans bore a floating rate tied to 1‑month SOFR with a 3.5% add‑on plus 5.25%, subject to a floor of 8.75%. Scheduled amortization would have begun on July 1, 2028, but the company chose early repayment, eliminating future interest and covenant requirements tied to this facility.